Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
GlaxoSmithKline
Upon determination of eligibility, all patients will be receive:
Paclitaxel + Carboplatin + Topotecan
a maximum of six courses of chemotherapy will be given at 21 day intervals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
To be included in this study, you must meet the following criteria:
Epithelial ovarian carcinoma or primary peritoneal carcinoma
Willing to consider second-look surgery to evaluate response if necessary
No previous treatment with chemotherapy or radiation therapy
Ability to perform activities of daily living with minimal assistance
Adequate bone marrow, liver and kidney function
Written informed consent
You may not be if
You cannot participate in this study if any of the following apply to you:
Age \< 18 years
Brain metastases
Recent history of significant heart disease within 6 months
Other significant medical conditions
Clareo Health | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
